2 december 2017: klik op de titel

Key Points

  • In patients with triple-negative breast cancer, an absolute increase in the estimated pathologic complete response rate of 40% was observed in the pembrolizumab arm.
  • In patients with HER2-negative breast cancer, an absolute increase in the estimated pathologic complete response rate of 30% was observed in the pembrolizumab arm.
  • In patients with hormone receptor–positive/HER2-negative breast cancer, an absolute increase in the estimated pathologic complete response rate of 21% was observed in the pembrolizumab arm.

Gerelateerde artikelen